A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission (NCT05197426)

🧪 Interventions in This Study

• Oral Azacitidine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (31 Sites)

Showing the first 25 of 31 sites.

• Local Institution - 0011 — Huntsville, Alabama
• Local Institution - 0017 — Nagoya, Aichi-ken
• Local Institution - 0023 — Nagoya, Aichi-ken
• Local Institution - 0009 — Toyoake, Aichi-ken
• Local Institution - 0022 — Aomori, Aomori
• Local Institution - 0005 — Kamogawa, Chiba
• Local Institution - 0003 — Kashiwa-shi, Chiba
• Local Institution - 0010 — Matsuyama, Ehime
• Local Institution - 0020 — Yoshida Gun, Fukui
• Local Institution - 0016 — Fukuoka, Fukuoka
• Local Institution - 0014 — Ōgaki, Gifu
• Local Institution - 0001 — Maebashi, Gunma
• Local Institution - 0004 — Sapporo, Hokkaido
• Local Institution - 0019 — Kanazawa, Ishikawa-ken
• Local Institution - 0012 — Isehara, Kanagawa
• Local Institution - 0006 — Sagamihara-shi, Kanagawa
• Local Institution - 0013 — Yokohama, Kanagawa
• Local Institution - 0015 — Sendai, Miyagi
• Local Institution - 0026 — Osaka, Osaka
• Local Institution - 0021 — Ōsaka-sayama, Osaka
• Local Institution - 0031 — Shimotsuke, Tochigi
• Local Institution - 0032 — Bunkyo Ku, Tokyo
• Local Institution - 0002 — Shinagawa, Tokyo
• Local Institution - 0030 — Shinjuku-ku, Tokyo
• Local Institution - 0029 — Sumida Ku, Tokyo

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukemia

• PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
• Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
• A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
• A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California

Explore by condition: All Acute Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.